Compare Oatly Group AB - ADR (OTLY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs TG Therapeutics Inc — how do they compare? Oatly Group AB - ADR trades at $10.59 (market cap $330.93M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 24.7× Oatly Group AB - ADR's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and TG Therapeutics Inc for 16 Days on average.
| OTLY | TGTX | |
|---|---|---|
Market Cap | $330.93M | $8.16B |
Volume | 68,708 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $59.06 |
52-Week Low | $8.03 | $26.94 |
Typical Hold Time | 18 Days | 16 Days |
Enterprise Value | $835.34M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.38 with minimal daily movement (+0.1%). The stock shows mixed signals with a bearish technical outlook but improving fundamentals. Recent Q2 2026 results showed revenue growth and margin improvement, though the company continues to post net losses. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The investment case hinges on Oatly's ongoing turnaround efforts showing progress through revenue growth and margin expansion. Key risks include persistent negative cash flow, high debt levels, and delayed profitability. The stock offers speculative appeal for investors betting on the plant-based beverage market growth and operational improvements, but requires careful risk management.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
